Last 32 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.52 | 1.83 | 3.06 | 3.91 | 5.32 | 4.36 | 4.40 | 3.96 | 4.86 | 17.86 | 20.59 | 81.05 | 191.75 | — | — | — | — | — | — | — | — |
| — | -58.1% | -30.5% | -1.2% | +9.4% | -75.6% | -78.6% | -95.1% | -97.5% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 39.46 | — | — | — | — | 13.61 | 10.29 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +64.1% | +76.7% | |
| P/FCF | — | 79.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 4307.97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 101.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.1% | 78.3% | 79.7% | 79.4% | 86.7% | 87.5% | 87.2% | 86.9% | 87.1% | 85.6% | 81.2% | 77.7% | 48.4% | — | — | — | — | — | — | — | — |
| — | -10.5% | -8.7% | -8.6% | -0.5% | +2.2% | +7.4% | +11.9% | +80.1% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -91.4% | -0.1% | -5.3% | -26.5% | -10.3% | -30.8% | -151.7% | -276.5% | -200.3% | -433.0% | -1055.4% | -3658.7% | -10245.5% | — | — | — | — | — | — | — | — |
| — | +99.7% | +96.5% | +90.4% | +94.9% | +92.9% | +85.6% | +92.4% | +98.0% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -126.3% | -16.4% | -23.7% | -52.1% | -36.7% | -60.5% | -191.9% | -330.7% | -251.0% | -523.3% | -1248.6% | -4333.3% | -11667.0% | — | — | — | — | — | — | — | — |
| — | +72.9% | +87.7% | +84.2% | +85.4% | +88.4% | +84.6% | +92.4% | +97.8% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -232.8% | — | — | — | -328.1% | -73.8% | -40.8% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +29.1% | — | — | — | -1230.8% | -279.8% | -33.1% | |
| ROA | -69.4% | -4.1% | -5.6% | -10.8% | -8.5% | -12.2% | -27.8% | -28.0% | -19.5% | -24.2% | -27.1% | -21.5% | -24.5% | -17.2% | -20.0% | -24.5% | -30.0% | -24.6% | -28.1% | -24.0% | -17.1% |
| — | +66.2% | +80.0% | +61.6% | +56.5% | +49.6% | -2.9% | -30.4% | +20.4% | -40.6% | -35.1% | +12.2% | +18.5% | +30.0% | +28.7% | -1.9% | -75.0% | -48.6% | -77.1% | -86.7% | +16.0% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 12.47 | — | — | — | — | 2.43 | 1.27 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +703.9% | +401.7% | |
| Debt / EBITDA | — | 4798.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.73 | 1.76 | 1.92 | 2.21 | 1.73 | 2.23 | 2.38 | 3.58 | 4.20 | 5.73 | 6.48 | 7.83 | 10.25 | 9.46 | 11.96 | 9.68 | 6.12 | 8.60 | 9.93 | 12.79 | 9.86 |
| — | -21.1% | -19.3% | -38.2% | -58.7% | -61.0% | -63.2% | -54.3% | -59.0% | -39.4% | -45.8% | -19.1% | +67.5% | +9.9% | +20.5% | -24.3% | -37.9% | +6.2% | +86.1% | +115.2% | +87.9% | |
| Quick Ratio | 1.69 | 1.72 | 1.87 | 2.16 | 1.69 | 2.19 | 2.35 | 3.54 | 4.16 | 5.68 | 6.44 | 7.80 | 10.22 | 9.45 | 11.96 | 9.68 | 6.12 | 8.60 | 9.93 | 12.79 | 9.86 |
| — | -21.7% | -20.1% | -38.9% | -59.4% | -61.4% | -63.6% | -54.7% | -59.2% | -39.9% | -46.2% | -19.5% | +67.0% | +9.8% | +20.4% | -24.3% | -37.9% | +6.2% | +86.1% | +115.2% | +87.8% | |
| Interest Coverage | -2.25 | 0.10 | -0.16 | -0.92 | -0.29 | -0.86 | -3.33 | -4.22 | -3.00 | -3.63 | -4.15 | -3.83 | -5.11 | -3.28 | -3.26 | -3.10 | -4.73 | -4.51 | -7.99 | -13.74 | -11.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PHAT stock.
Phathom Pharmaceuticals, Inc.'s current P/E is -5.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Phathom Pharmaceuticals, Inc.'s current operating margin is -91.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Phathom Pharmaceuticals, Inc.'s business trajectory between earnings reports.